Taysha Gene Therapies Inc (NAS:TSHA)
$ 1.93 0.05 (2.66%) Market Cap: 395.54 Mil Enterprise Value: 290.14 Mil PE Ratio: 0 PB Ratio: 4.49 GF Score: 36/100

Q2 2023 Taysha Gene Therapies Inc Earnings Call Transcript

Aug 14, 2023 / 12:30PM GMT
Release Date Price: $2.13 (+188.23%)
Operator

Good morning. Welcome to Taysha Gene Therapies Second Quarter 2023 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this webcast is being recorded today, August 14, 2020.

I will now turn the call over to Hayleigh Collins, Director, Head of Corporate Communications. Please go ahead.

Hayleigh Collins
Taysha Gene Therapies, Inc. - Director & Head of Corporate Communications

Thank you. Good morning, and welcome to Taysha's second quarter 2023 financial results and corporate update conference call.

Earlier today, Taysha issued a press release announcing financial results for the second quarter of 2023. A copy of this press release is available on the company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Taysha's CEO; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. (Operator Instructions)

Please note that on today's call, we will be making forward-looking statements, including statements relating to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot